New shot aims to boost immunity against HPV in HIV patients
NCT ID NCT07090174
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 33 times
Summary
This study tests an immunotherapy called PDS0101 in 27 adults with both HIV and HPV 16. The goal is to see if it is safe and can strengthen the immune system's response against HPV, which can cause cancers like anal and cervical cancer. All participants will receive three doses of the vaccine, and researchers will monitor for side effects and immune changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montefiore Medical Center/Albert Einstein College of Medicine
The Bronx, New York, 10461, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Puerto Rico
San Juan, 00935, Puerto Rico
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Weill Cornell Medical College
New York, New York, 10010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PDS0101 (HPV 16-targeted immunotherapy with Versamune® adjuvant)
What this could lead to
If successful, this could point toward a way to help people with HIV clear HPV 16 infections and reduce their risk of HPV-related cancers.
What could go wrong
This is an early Phase 2 trial with only 27 participants, so results may not apply to everyone. The treatment may cause side effects like injection site reactions, and it is not yet known if it will effectively prevent cancer.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.